Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9364339 | 0.84 | MAPK1 (0.62) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL536696 | 0.84 | MAPK1 (0.62) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL17036528 | 0.83 | MAPK1 (0.57) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL4151771 | 0.81 | MAPK1 (0.68) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL31236317 | 0.80 | MAPK1 (0.66) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL3027838 | 0.80 | MAPK1 (0.66) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL904819 | 0.78 | MAPK1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL23339264 | 0.76 | SLC6A2 (0.48) | HPGDALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL9210565 | 0.75 | ALDH1A1 (0.72) | MAPK1TSHRHPGDUSP2ALDH1A1 | |
| SCHEMBL5542532 | 0.74 | HPGD (0.65) | MAPK1TSHRHPGDUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828396-B2 | Alkyne compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | MAPK1 1077/4885TSHR 1336/4885HPGD 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.